Comparative Pharmacology
Head-to-head clinical analysis: HER STYLE versus SELFEMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HER STYLE versus SELFEMRA.
HER STYLE vs SELFEMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HER STYLE is a hormonal contraceptive containing ethinyl estradiol and levonorgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. It also thickens cervical mucus to impede sperm penetration and alters endometrial lining to prevent implantation.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptor alpha (ERα), inducing its degradation and inhibiting estrogen-dependent cell proliferation.
Not applicable. HER STYLE is not a recognized pharmaceutical agent; no standard dosing available.
1 tablet (50 mg) orally once daily with food.
None Documented
None Documented
Terminal half-life: 12 hours (range 10–14 hours). Clinical context: Allows twice-daily dosing; steady-state achieved in ~2.5 days.
Terminal elimination half-life of 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10%.
Primarily renal excretion as unchanged drug (50-60%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal